https://novapharmanews.com/us/news/fda-approves-belzutifan-plus-pembrolizumab-adjuvant-rcc 2026-06-15T14:05:59.564Z NovaPharmaNews en 2026-06-15T14:05:59.625Z FDA approves belzutifan plus pembrolizumab for adjuvant RCC belzutifan, Welireg, pembrolizumab, Keytruda, berahyaluronidase, renal cell carcinoma, advanced renal cell carcinoma, clear cell renal cell carcinoma https://novapharmanews.com/uploads/articles/fda-approves-belzutifan-plus-pembrolizumab-adjuvant-rcc.webp FDA approves belzutifan plus pembrolizumab for adjuvant RCC https://novapharmanews.com/apac/news/piyush-goyal-invites-global-pharma-firms-to-partner-with-india 2026-06-15T14:09:26.370Z NovaPharmaNews en 2026-06-15T12:02:53.384Z Piyush Goyal Invites Global Pharma Firms to Partner With India https://novapharmanews.com/uploads/articles/piyush-goyal-invites-global-pharma-firms-to-partner-with-india.webp Piyush Goyal Invites Global Pharma Firms to Partner With India https://novapharmanews.com/us/news/prescription-drug-freight-fraud-june-2026-report 2026-06-15T13:04:01.251Z NovaPharmaNews en 2026-06-15T10:10:51.698Z Prescription Drug Freight Fraud June 2026 report: what the record shows https://novapharmanews.com/uploads/articles/prescription-drug-freight-fraud-june-2026-report.webp Prescription Drug Freight Fraud June 2026 report: what the record shows https://novapharmanews.com/us/news/planning-a-successful-pivot-from-lab-to-clinic-practical-career-map 2026-06-15T15:41:29.615Z NovaPharmaNews en 2026-06-15T10:10:51.226Z Planning a successful pivot from lab to clinic: a practical career map https://novapharmanews.com/uploads/articles/planning-a-successful-pivot-from-lab-to-clinic-practical-career-map.webp Planning a successful pivot from lab to clinic: a practical career map https://novapharmanews.com/eu/news/truqap-combo-wins-new-approval-us-pten-deficient-prostate-cancer 2026-06-15T10:04:49.933Z NovaPharmaNews en 2026-06-14T16:33:22.670Z Truqap combo wins new US approval in PTEN-deficient prostate cancer Truqap, capivasertib, abiraterone, prednisone, Oncology https://novapharmanews.com/uploads/articles/truqap-combo-wins-new-approval-us-pten-deficient-prostate-cancer.webp Truqap combo wins new US approval in PTEN-deficient prostate cancer https://novapharmanews.com/eu/news/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc 2026-06-15T12:19:37.244Z NovaPharmaNews en 2026-06-14T12:41:57.231Z FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC capivasertib, Truqap, abiraterone, Zytiga, prednisone, prednisolone, abiraterone acetate, prostate cancer, metastatic androgen pathway modulation-naive prostate cancer, metastatic androgen pathway modulation-sensitive prostate cancer https://novapharmanews.com/uploads/articles/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc.webp FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC https://novapharmanews.com/eu/news/china-big-pharma-essential-rd-partner 2026-06-15T14:01:09.426Z NovaPharmaNews en 2026-06-14T12:41:56.401Z China Becomes Big Pharma's Essential R&D Partner https://novapharmanews.com/uploads/articles/china-big-pharma-essential-rd-partner.webp China Becomes Big Pharma's Essential R&D Partner